StreetInsider.com News Articles

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Wed, 27 May 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June:

Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 3, 2026, at 11:40 a.m. ET. Management will also be participating in one-on-one meetings.

Goldman Sachs 47th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 9, 2026, at

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Wed, 27 May 2026 16:05:00 -0400

Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 3, 2026, at 11:40 a.m. ET. Management will also be participating in one-on-one meetings.

Goldman Sachs 47th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 9, 2026, at

ORIC Pharmaceuticals (ORIC) Reiterated at Overweight by Cantor Fitzgerald

Fri, 22 May 2026 07:26:47 -0400

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC).

The analyst commented, "KOLs are cautiously optimistic about Pfizer's (PFE, N) mevrometostat in the Ph3 MEVPRO-1 trial, which also has important read-throughs to ORIC (OW). KOLs assigned a 60% PoS to MEVPRO-1, as they were positive on mevrometostat’s active-controlled data that showed rPFS HR of 0.51, but acknowledged the typical risks of moving from a small sample trial (n=80) to a larger Ph3 (n=600). KOLs viewed a median rPFS of 11 months for mevro, compared with expectation of ~7-8 months rPFS for the control arm, as a

Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP

Fri, 15 May 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26508108.html

Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP

Fri, 15 May 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26508108.html

Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 15 May 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260515/26506906.html

Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 15 May 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260515/26506906.html

Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26506046.html

Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26506046.html

Form SCHEDULE 13G Oric Pharmaceuticals, Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 15 May 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501306.html

Form SCHEDULE 13G Oric Pharmaceuticals, Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 15 May 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501306.html

Goldman Sachs Upgrades ORIC Pharmaceuticals (ORIC) to Buy

Fri, 15 May 2026 05:10:15 -0400

Goldman Sachs analyst Corinne Johnson upgraded ORIC Pharmaceuticals (NASDAQ: ORIC) from Early-Stage Biotech to Buy with a price target of $15.00.

The analyst comments "We move ORIC to a Buy rating (from Early Stage Biotech) following clinical data which demonstrated a potentially differentiated profile for rinzimetostat in prostate cancer (GSe: $2.6B peak sales), and ahead of key de-risking Ph3 data for the class in MEVPRO-1 (expected in 2026). We view the key debate for the stock as whether rinzimetostat can realize multi-blockbuster revenue potential in prostate cancer, with outstanding questions on both the class (PRC2 inhibition) and profile of rinzi to

Goldman Sachs Upgrades ORIC Pharmaceuticals (ORIC) to Buy

Fri, 15 May 2026 05:10:15 -0400

Goldman Sachs analyst Corinne Johnson upgraded ORIC Pharmaceuticals (NASDAQ: ORIC) from Early-Stage Biotech to Buy with a price target of $15.00.

Goldman Sachs Upgrades ORIC Pharmaceuticals (ORIC) to Buy

Fri, 15 May 2026 05:10:15 -0400

Goldman Sachs analyst Corinne Johnson upgraded ORIC Pharmaceuticals (NASDAQ: ORIC) from Early-Stage Biotech to Buy with a price target of $15.00.

Goldman Sachs Upgrades ORIC Pharmaceuticals (ORIC) to Buy

Fri, 15 May 2026 05:10:15 -0400

Goldman Sachs analyst Corinne Johnson upgraded ORIC Pharmaceuticals (NASDAQ: ORIC) from Early-Stage Biotech to Buy with a price target of $15.00.

Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: PFIZER INC

Tue, 12 May 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260512/26479183.html

Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: PFIZER INC

Tue, 12 May 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260512/26479183.html

ORIC Pharmaceuticals, Inc. (ORIC) Misses Q1 EPS by 2c

Mon, 04 May 2026 16:28:08 -0400

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported Q1 EPS of ($0.34), $0.02 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on ORIC Pharmaceuticals, Inc. (ORIC) click here.

Form 10-Q Oric Pharmaceuticals, For: Mar 31

Mon, 04 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260504/26426083.html

Form 10-Q Oric Pharmaceuticals, For: Mar 31

Mon, 04 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260504/26426083.html

Form 8-K Oric Pharmaceuticals, For: May 04

Mon, 04 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260504/26425710.html

Form 8-K Oric Pharmaceuticals, For: May 04

Mon, 04 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260504/26425710.html

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

Mon, 04 May 2026 16:05:00 -0400

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026

Reported rinzimetostat data in post-abiraterone mCRPC supporting potential best-in-disease profile, including a highly differentiated safety profile and landmark rPFS consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC

Reported early rinzimetostat data in post-AR inhibitor mCRPC, demonstrating promising durability and reinforcing rinzimetostat’s potential to restore and sustain the benefit derived from AR inhibitors

Anticipate rinzimetostat program update in 2H 2026 and several

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

Mon, 04 May 2026 16:05:00 -0400

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026

Reported rinzimetostat data in post-abiraterone mCRPC supporting potential best-in-disease profile, including a highly differentiated safety profile and landmark rPFS consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC

Reported early rinzimetostat data in post-AR inhibitor mCRPC, demonstrating promising durability and reinforcing rinzimetostat’s potential to restore and sustain the benefit derived from AR inhibitors

Anticipate rinzimetostat program update in 2H 2026 and several

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 01 May 2026 16:30:00 -0400

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2026 (the “Grant Date”), ORIC granted a total of 216,000 non-qualified stock options and 35,000 restricted stock units to four new non-executive employees who began their employment with ORIC in April 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each